• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Individuals cannot rely on COVID-19 herd immunity: Durable immunity to viral disease is limited to viruses with obligate viremic spread.

作者信息

Yewdell Jonathan W

机构信息

Cellular Biology Section, Laboratory of Viral Diseases, NIAID, Bethesda, Maryland, United States of America.

出版信息

PLoS Pathog. 2021 Apr 26;17(4):e1009509. doi: 10.1371/journal.ppat.1009509. eCollection 2021 Apr.

DOI:10.1371/journal.ppat.1009509
PMID:33901246
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8075217/
Abstract
摘要

相似文献

1
Individuals cannot rely on COVID-19 herd immunity: Durable immunity to viral disease is limited to viruses with obligate viremic spread.个体不能依赖新冠病毒群体免疫：对病毒性疾病的持久免疫力仅限于具有专性病毒血症传播的病毒。
PLoS Pathog. 2021 Apr 26;17(4):e1009509. doi: 10.1371/journal.ppat.1009509. eCollection 2021 Apr.
2
Contact-adjusted Immunity Levels against SARS-CoV-2 in Korea and Prospects for Achieving Herd Immunity.韩国针对 SARS-CoV-2 的接触调整免疫水平和实现群体免疫的前景。
J Korean Med Sci. 2021 Oct 4;36(38):e272. doi: 10.3346/jkms.2021.36.e272.
3
Herd immunization with childhood vaccination may provide protection against COVID-19.群体免疫接种儿童疫苗可能对预防 COVID-19 提供保护。
Acta Microbiol Immunol Hung. 2020 Sep 26;67(3):198-200. doi: 10.1556/030.2020.01207.
4
How to Understand Herd Immunity in the Context of COVID-19.如何理解 COVID-19 大流行中的群体免疫。
Viral Immunol. 2021 Apr;34(3):174-181. doi: 10.1089/vim.2020.0195. Epub 2020 Dec 21.
5
Could COVID-19 be contained in poor populations by herd immunity rather than by strategies designed for affluent societies or potential vaccine(s)?新冠病毒肺炎能否通过群体免疫而非为富裕社会或潜在疫苗设计的策略在贫困人口中得到控制？
Glob Health Action. 2021 Jan 1;14(1):1863129. doi: 10.1080/16549716.2020.1863129.
6
COVID-19 and immunity: quo vadis?COVID-19 与免疫：何去何从？
Int Immunol. 2021 Sep 25;33(10):507-513. doi: 10.1093/intimm/dxab008.
7
Five reasons why COVID herd immunity is probably impossible.新冠病毒群体免疫可能无法实现的五个原因。
Nature. 2021 Mar;591(7851):520-522. doi: 10.1038/d41586-021-00728-2.
8
COVID-19 vaccines and herd immunity: Perspectives, challenges and prospects.COVID-19 疫苗与群体免疫：观点、挑战与展望。
Malays J Pathol. 2021 Aug;43(2):203-217.
9
Achieving herd immunity against COVID-19 at the country level by the exit strategy of a phased lift of control.通过分阶段放宽控制的退出策略，在国家层面上实现对 COVID-19 的群体免疫。
Sci Rep. 2021 Feb 24;11(1):4445. doi: 10.1038/s41598-021-83492-7.
10
Are COVID vaccination programmes working? Scientists seek first clues.新冠疫苗接种计划是否有效？科学家们寻找初步线索。
Nature. 2021 Jan;589(7843):504-505. doi: 10.1038/d41586-021-00140-w.

引用本文的文献

1
Long-Circulating Nanobody Confers Durable Prophylaxis against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection.长效循环纳米抗体赋予对严重急性呼吸综合征冠状病毒2奥密克戎感染的持久预防作用。
Adv Nanobiomed Res. 2025 Aug;5(8). doi: 10.1002/anbr.202400214. Epub 2025 Jun 27.
2
Quantifying the waning of humoral immunity.量化体液免疫的减弱。
medRxiv. 2025 May 14:2025.05.13.25327542. doi: 10.1101/2025.05.13.25327542.
3
Waning immunity drives respiratory virus evolution and reinfection.免疫力下降推动呼吸道病毒进化和再次感染。
Evol Med Public Health. 2025 Jan 31;13(1):101-110. doi: 10.1093/emph/eoaf002. eCollection 2025.
4
Jonathan Yewdell Discusses Viral Immunology, Vaccine Development, Navigating a Scientific Career, and Offers Perspectives on Transforming Scientific Publishing and Research Education.乔纳森·尤德尔讨论了病毒免疫学、疫苗开发、科学职业生涯规划，并就科学出版和研究教育的变革发表了看法。
Pathog Immun. 2024 Sep 27;9(2):94-134. doi: 10.20411/pai.v9i2.753. eCollection 2024.
5
Waning immunity drives respiratory virus evolution and reinfection.免疫力下降推动呼吸道病毒进化和再感染。
bioRxiv. 2024 Aug 8:2024.07.23.604867. doi: 10.1101/2024.07.23.604867.
6
Tetanus-diphtheria vaccine can prime SARS-CoV-2 cross-reactive T cells.破伤风白喉疫苗可激发对 SARS-CoV-2 具有交叉反应性的 T 细胞。
Front Immunol. 2024 Jul 18;15:1425374. doi: 10.3389/fimmu.2024.1425374. eCollection 2024.
7
Recombinant OC43 SARS-CoV-2 spike replacement virus: An improved BSL-2 proxy virus for SARS-CoV-2 neutralization assays.重组 OC43 SARS-CoV-2 刺突替代病毒：一种用于 SARS-CoV-2 中和测定的改良 BSL-2 替代病毒。
Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2310421121. doi: 10.1073/pnas.2310421121. Epub 2024 Jul 8.
8
Use of Immunoglobulin Y Antibodies: Biosensor-based Diagnostic Systems and Prophylactic and Therapeutic Drug Delivery Systems for Viral Respiratory Diseases.免疫球蛋白Y抗体的应用：基于生物传感器的病毒呼吸道疾病诊断系统以及预防和治疗性药物递送系统
Curr Top Med Chem. 2024;24(11):973-985. doi: 10.2174/0115680266289898240322073258.
9
Rivalry between Humans and Coronaviruses: Unanticipated Impact of Omicron.人类与冠状病毒之间的对抗：奥密克戎的意外影响
Women Health Care Issues. 2022;5(2). doi: 10.31579/2642-9756/109. Epub 2022 Mar 8.
10
Recombinant transmissible vaccines will be intrinsically contained despite the ability to superinfect.重组传染性疫苗将具有内在的包容性，尽管有超强感染的能力。
Expert Rev Vaccines. 2024 Jan-Dec;23(1):294-302. doi: 10.1080/14760584.2024.2320845. Epub 2024 Feb 28.

本文引用的文献

1
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.SARS-CoV-2 变异株对单克隆和血清来源的多克隆抗体中和作用的抗性。
Nat Med. 2021 Apr;27(4):717-726. doi: 10.1038/s41591-021-01294-w. Epub 2021 Mar 4.
2
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.预测用于治疗 COVID-19 的抗体所识别的病毒突变逃逸情况。
Science. 2021 Feb 19;371(6531):850-854. doi: 10.1126/science.abf9302. Epub 2021 Jan 25.
3
Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229e.季节性冠状病毒 OC43 和 229e 受体结合域中的适应性进化证据。
Elife. 2021 Jan 19;10:e64509. doi: 10.7554/eLife.64509.
4
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
5
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
6
COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses.COVID-19 疫苗 BNT162b1 可引发人体抗体和 T1 T 细胞应答。
Nature. 2020 Oct;586(7830):594-599. doi: 10.1038/s41586-020-2814-7. Epub 2020 Sep 30.
7
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.轻度新冠肺炎患者体内抗SARS-CoV-2抗体的快速衰减
N Engl J Med. 2020 Sep 10;383(11):1085-1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.
8
Virus interactions with bacteria: Partners in the infectious dance.病毒与细菌的相互作用：感染之舞中的伙伴。
PLoS Pathog. 2020 Feb 11;16(2):e1008234. doi: 10.1371/journal.ppat.1008234. eCollection 2020 Feb.
9
Bacteria Facilitate Enteric Virus Co-infection of Mammalian Cells and Promote Genetic Recombination.细菌促进肠道病毒感染哺乳动物细胞并促进基因重组。
Cell Host Microbe. 2018 Jan 10;23(1):77-88.e5. doi: 10.1016/j.chom.2017.11.007. Epub 2017 Dec 28.
10
Selective IgA Deficiency: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management.选择性IgA缺乏症：流行病学、发病机制、临床表型、诊断、预后及管理
Scand J Immunol. 2017 Jan;85(1):3-12. doi: 10.1111/sji.12499.